Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 6/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2641383 | 1.00 | CA1 (0.50) | CA1CA2CA7KLK5CTSK | |
| SCHEMBL28367402 | 0.85 | CA1 (0.51) | CA1CA2CA7KLK5CTSK | |
| SCHEMBL28367401 | 0.85 | CA1 (0.51) | CA1CA2CA7KLK5CTSK | |
| SCHEMBL10724721 | 0.84 | CA1 (0.55) | CA1CA2CA7KLK5CTSK | |
| SCHEMBL15757399 | 0.84 | CA1 (0.47) | CA1CA2CA7KLK5CTSK | |
| SCHEMBL741043 | 0.84 | CA1 (0.55) | CA1CA2CA7KLK5CTSK | |
| SCHEMBL19618687 | 0.84 | CA1 (0.55) | CA1CA2CA7KLK5CTSK | |
| SCHEMBL5564464 | 0.84 | CA1 (0.55) | CA1CA2CA7KLK5CTSK | |
| SCHEMBL10724727 | 0.84 | CA1 (0.55) | CA1CA2CA7KLK5CTSK | |
| SCHEMBL15757401 | 0.84 | CA1 (0.47) | CA1CA2CA7KLK5CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569324-B9 | AMINOGLYCOSIDE DERIVATIVES | REMPEX PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2569324-B9 | AMINOGLYCOSIDE DERIVATIVES | REMPEX PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2569324-B1 | AMINOGLYCOSIDE DERIVATIVES | REMPEX PHARMACEUTICALS INC (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2569324-B1 | AMINOGLYCOSIDE DERIVATIVES | REMPEX PHARMACEUTICALS INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-8906868-B2 | Aminoglycoside derivatives | REMPEX PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906868-B2 | Aminoglycoside derivatives | REMPEX PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906868-B2 | Aminoglycoside derivatives | REMPEX PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2569324-A1 | AMINOGLYCOSIDE DERIVATIVES | Rempex Pharmaceuticals, Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20130059808-A1 | AMINOGLYCOSIDE DERIVATIVES | REMPEX PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059808-A1 | AMINOGLYCOSIDE DERIVATIVES | REMPEX PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011143497-A1 | AMINOGLYCOSIDE DERIVATIVES | REMPEX PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143497-A1 | AMINOGLYCOSIDE DERIVATIVES | REMPEX PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059808-A1 | AMINOGLYCOSIDE DERIVATIVES | AMPD3, ALG8, MRPL21 | CA1 4717/4885CA2 3153/4885CA7 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.